Free Trial

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Iovance Biotherapeutics logo
$2.68 +0.11 (+4.28%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.75 +0.07 (+2.46%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Key Stats

Today's Range
$2.45
$2.71
50-Day Range
$1.69
$3.97
52-Week Range
$1.64
$12.51
Volume
16.65 million shs
Average Volume
25.14 million shs
Market Capitalization
$894.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.22
Consensus Rating
Hold

Company Overview

Iovance Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
89th Percentile Overall Score

IOVA MarketRank™: 

Iovance Biotherapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 108th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Iovance Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Iovance Biotherapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Iovance Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Iovance Biotherapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Iovance Biotherapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Iovance Biotherapeutics has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Iovance Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    36.34% of the float of Iovance Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iovance Biotherapeutics has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Iovance Biotherapeutics has recently increased by 1.91%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Iovance Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Iovance Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    36.34% of the float of Iovance Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iovance Biotherapeutics has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Iovance Biotherapeutics has recently increased by 1.91%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Iovance Biotherapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Iovance Biotherapeutics this week, compared to 12 articles on an average week.
  • Search Interest

    69 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 130% compared to the previous 30 days.
  • MarketBeat Follows

    23 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 53% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,744.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.30% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Iovance Biotherapeutics' insider trading history.
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Stock News Headlines

This Crypto Is Set to Explode in January
Free summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…
Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO
See More Headlines

IOVA Stock Analysis - Frequently Asked Questions

Iovance Biotherapeutics' stock was trading at $7.40 on January 1st, 2025. Since then, IOVA shares have decreased by 63.8% and is now trading at $2.68.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.11. The business's quarterly revenue was up 6795.1% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Iovance Biotherapeutics include Aberdeen Group plc (0.15%), Teacher Retirement System of Texas (0.02%), Caliber Wealth Management LLC KS (0.02%) and Envestnet Asset Management Inc. (0.01%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Raj K Puri, Iain D Dukes, Ryan D Maynard and Frederick G Vogt.
View institutional ownership trends
.

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/08/2025
Today
8/02/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IOVA
CIK
1425205
Fax
N/A
Employees
500
Year Founded
2013

Price Target and Rating

High Price Target
$25.00
Low Price Target
$2.00
Potential Upside/Downside
+356.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$372.18 million
Net Margins
-176.49%
Pretax Margin
-178.02%
Return on Equity
-49.71%
Return on Assets
-39.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.18
Quick Ratio
3.64

Sales & Book Value

Annual Sales
$164.07 million
Price / Sales
5.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.33 per share
Price / Book
1.15

Miscellaneous

Outstanding Shares
333,930,000
Free Float
299,539,000
Market Cap
$894.93 million
Optionable
Optionable
Beta
0.87

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:IOVA) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners